Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IV Iron Isomaltoside vs Oral Iron in Pregnancy
NCT03188445Phase 4Completed
- Sponsor
- Pharmacosmos
- Start
- Jul 2017
- Primary completion
- Jun 2020
- Modality
- Inorganic Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ferric derisomaltose in iron deficiency anemia (IDA) (2 arms), sponsored by Pharmacosmos. Primary endpoint: Achievement of hemoglobin equal or above 11 g/dL at 18 weeks. Started Jul 2017; status: completed.
02
Drugs
ferric derisomaltose
03
Conditions
iron deficiency anemia (IDA)
Beyond the preview
Go deeper on NCT03188445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03188445.